Close

Form 6-K DR REDDYS LABORATORIES For: Nov 05

November 5, 2015 2:35 PM EST

 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

Form 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13A-16 OR 15D-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Month of September 2015

Commission File Number 1-15182

 

 

DR. REDDY’S LABORATORIES LIMITED

(Translation of registrant’s name into English)

 

 

8-2-337, Road No. 3, Banjara Hills

Hyderabad, Telangana 500 034, India

+91-40-49002900

(Address of principal executive office)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  x            Form 40-F  ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ¨

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ¨

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

    Yes  ¨            No  x

If “Yes” is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-            .

 

 

 


EXHIBITS

 

Exhibit Number

  

Description of Exhibits

99.1    Press Release, “Dr. Reddy’s launches MINTOP PRO TM – ProcapilTM Hair Therapy,” September 4, 2015.
99.2    Press Release, “PanTheryx and Dr. Reddy’s Announce an Agreement to Market PanTheryx’s Proprietary Nutritional Intervention for Pediatric Infectious Diarrhea,” September 9, 2015.
99.3    Press Release, “Dr. Reddy’s Laboratories signs commercialization deal with Hatchtech,” September 14, 2015.
99.4    Press Release, “Dr. Reddy’s announces the Launch of Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg and 40 mg,” September 28, 2015.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

DR. REDDY’S LABORATORIES LIMITED

(Registrant)

Date: November 5, 2015   By:   /s/ Sandeep Poddar
   

 

    Name:   Sandeep Poddar
    Title:   Company Secretary

Exhibit 99.1

 

 

LOGO

 

DR. REDDY’S LABORATORIES LTD.

8-2-337, Road No. 3, Banjara Hills,

Hyderabad - 500034. Telangana, India.

   CONTACT
   INVESTOR RELATIONS    MEDIA RELATIONS
   KEDAR UPADHYE
[email protected]

(Ph: +91-40-66834297)

   CALVIN PRINTER
[email protected]
(Ph: +91-40- 49002121)
     

 

 

Dr. Reddy’s launches MINTOP PRO TM – ProcapilTM Hair Therapy

Hyderabad, India, September 4, 2015

 

Dr. Reddy’s Laboratories (NYSE: RDY) has announced its entry into the Hair Serum Market with the launch of MINTOP PROTM - Procapil Hair Therapy. MINTOP PROTM comes from the same branch of business that manufactures MINTOP - the No. 1 dermatologist recommended brand in the country.1

Studies reveal that Androgenetic alopecia (AGA) is one of the most common reasons for dermatological consultation. This type of hair loss has been reported in 58%2 of middle-age men and 19%3 of women and there have been rapid advancements in understanding the pathophysiology of AGA over the last few years.

PROCAPILTM is a new breakthrough formula that strengthens hair and prevents excessive hair loss naturally, without any side effects. PROCAPILTM consists of a patented vitaminated matrikine with Apigenin and Oleanolic acid, which specifically targets the three main reasons responsible for hair loss.

Naturally derived Oleanolic acid inhibits the production of Dihydrotestosterone, a chemical derivative of testosterone, which plays a major role in hair loss in most men and some women. Apigenin enhances microcirculation into the hair follicles keeping it nourished, while Biotinyl-GHK helps normalize hair anchorage in the lower layer of skin thereby demonstrating anti – ageing properties.

Clinical studies reveal that, MINTOP PROTM demonstrated promising results with a 121% increase in hair shaft growth as compared to placebo and 67% volunteers witnessed a noteworthy rise in Anagen to Telogen Ratio of upto 46%. (A/T ratio or hair growth coefficient is the ratio of the number of anagen hairs to the number of telogen hairs, indicates the proportion of active hair follicles)

MINTOP PROTM will be available in a 75 ml pack with MRP of INR 995/- at all leading pharmacy stores across India.

References:

 

  1. SMSRC – Data on File

 

  2. Male Androgenetic Alopecia: Population-Based Study in 1,005 Subjects. International Journal of Trichology. 2009;1(2):131-133

 

  3. Incidence of female androgenetic alopecia (female pattern alopecia). Dermatol Surg. 2001 Jan;27(1):53-4.

 

  4. PROCAPIL Patent: WO 2012143845 A2

About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. is an integrated pharmaceutical company, committed to accelerating access to affordable and innovative medicines, because it believes Good Health Can’t Wait. Through its three businesses—Pharmaceutical Services & Active Ingredients , Global Generics and Proprietary Products – the company offers a portfolio of products and services that include active pharmaceutical ingredients, (APIs), custom pharmaceutical services, generics, biosimilars and differentiated formulations. With operations in 26 countries across the globe, the major therapeutic areas of Dr. Reddy’s are gastro-intestinal, cardiovascular, diabetology, oncology, pain management and anti-infectives. For more information, log on to: www.drreddys.com

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words “may”, “will”, “should”, “expects”, “plans”, “intends”, “anticipates”, “believes”, “estimates”, “predicts”, “potential”, or “continue” and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates , interest rates , persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganisation , including related integration issues.

The company assumes no obligation to update any information contained herein.

Exhibit 99.2

 

LOGO    LOGO

PanTheryx and Dr. Reddy’s Announce an Agreement to Market PanTheryx’s

Proprietary Nutritional Intervention for Pediatric Infectious Diarrhea

Boulder, CO USA and Hyderabad, India – September 09, 2015 – PanTheryx, Inc., a global medical nutrition company based in Boulder, Colorado, and Dr. Reddy’s Laboratories Ltd. (NYSE: RDY), a leading global pharmaceutical company, announced today a multi-country supply and licensing agreement. The agreement grants Dr. Reddy’s the exclusive right to market and distribute PanTheryx’s breakthrough nutritional intervention, DiaResQ®, for infectious diarrhea in India and Nepal and in process for Russia, Myanmar, Vietnam, Ukraine, Sri Lanka, Kazakhstan, Belarus, Jamaica, and select LATAM markets. Dr. Reddy’s will market the product in India and Nepal under the “Reliqua™” brand.

DiaResQ® helps promote intestinal repair and boost natural immune defenses, resulting in the restoration of normal digestive function. The product was recently recognized in Reimagining Global Health as one of the 30 leading healthcare innovations with great promise to transform global health by 2030.

“The opportunity to work with Dr. Reddy’s to broadly introduce DiaResQ® represents a significant milestone for our company,” said Mark A. Braman, President and CEO of PanTheryx. “Dr. Reddy’s is the recognized leader in the gastrointestinal market, and this agreement covers some of the largest and most promising markets throughout the world for PanTheryx and its products. This partnership further validates DiaResQ’s® potential to improve the well-being and quality of life of millions of children and their families globally.”

Dr. Reddy’s Co-chairman and CEO, GV Prasad stated “This innovative product will address a significant unmet need in the area of diarrhea. By adding Reliqua to our existing portfolio of gastrointestinal brands, Dr. Reddy’s can provide an important new tool for healthcare practitioners across the many markets we serve. Our agreement with PanTheryx is another step towards ensuring good health can be delivered to those who need it.”

Infectious diarrhea is a major world health challenge. Globally, approximately 1.7 billion cases occur annually in children under five. Almost 760,000 of these children under five die every year as a result of this condition. Pediatric infectious diarrhea kills nearly as many children as HIV/AIDS, malaria and measles combined. (Source: World Health Organization)

- more -


PanTheryx and Dr. Reddy’s — page 2

About PanTheryx:

Founded in 2007, PanTheryx is a global medical nutrition company based in Boulder, Colorado USA, and is dedicated to improving global health and quality of life through innovative life science. Utilizing its broad-based proprietary technology platform, PanTheryx is focused on the research, development and commercialization of medical nutrition products targeting the gastrointestinal microbiome. The company’s lead product, DiaResQ®, addresses infectious diarrhea, a leading cause of death worldwide among children under the age of five. For more information, log on to: www.pantheryx.com

About Dr. Reddy’s

Dr. Reddy’s Laboratories Ltd. is an integrated pharmaceutical company, committed to accelerating access to affordable and innovative medicines, because it believes Good Health Can’t Wait. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – the company offers a portfolio of products and services that include active pharmaceutical ingredients, (APIs), custom pharmaceutical services, generics, biosimilars and differentiated formulations. With operations in 26 countries across the globe, the major therapeutic areas of Dr. Reddy’s are gastro-intestinal, cardiovascular, diabetology, oncology, pain management and anti-infectives. For more information, log on to: www.drreddys.com

Media Contacts:

PanTheryx, Inc.

Rodney D Bell

303-807-3397

[email protected]

Amy Fletcher

720-350-3144

[email protected]

Dr. Reddy’s Laboratories Ltd.

8-2-337, Road No. 3, Banjara Hills

Hyderabad,

Telangana 500 034

Calvin Printer

+91.40.4900 2121

[email protected]

Exhibit 99.3

 

LOGO

 

 

DR. REDDY’S LABORATORIES LTD.

8-2-337, Road No. 3, Banjara Hills,

Hyderabad - 500034. Telangana, India.

   CONTACT
   INVESTOR RELATIONS    MEDIA RELATIONS
   KEDAR UPADHYE
[email protected]
(Ph: +91-40-66834297)
   CALVIN PRINTER
[email protected]
(Ph: +91-40- 49002121)

 

 

Dr. Reddy’s Laboratories signs commercialization deal with Hatchtech

Hyderabad, India, September 14, 2015

For immediate release

 

 

Dr. Reddy’s Laboratories (NYSE: RDY) today announced the signing of a commercialization deal with Hatchtech, an Australian pharmaceutical company developing an innovative prescription head lice product, Xeglyze™ Lotion. The exclusive rights for this product are applicable for the territories of the United States, Canada, India, Russia and the CIS, Australia, New Zealand and Venezuela.

Additionally, Hatchtech announced it will be filing its New Drug Application for Xeglyze™ with the US Food and Drug Administration (FDA) today. If approved, the product will be marketed in the United States by Promius Pharma, a wholly-owned specialty company of Dr. Reddy’s Laboratories.

As part of the agreement Dr. Reddy’s will pay Hatchtech an upfront amount of US $10MM, up to US$ 50 million based on pre commercialization milestones and an undisclosed amount based on post commercialization milestones, linked to achievement of annual net sales targets.

In September 2014, Hatchtech announced positive results from its two pivotal Phase 3 clinical studies evaluating Xeglyze™ Lotion as a potential treatment for head lice infestation. The studies involved 704 people, across 14 clinical trial sites in the US and resulted in an 81.5% success rate, following the observation period of 14 days after a single 10 minute application. Xeglyze™ Lotion, a topical formulation containing abametapir, an inhibitor of metalloproteases, has demonstrated both ovicidal and lousicidal activity and offers the potential for a more effective treatment using only a single application. The active drug substance was developed in collaboration with Dr. Reddy’s Custom Pharmaceutical Services (CPS) business unit.

About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. is an integrated pharmaceutical company, committed to accelerating access to affordable and innovative medicines, because it believes Good Health Can’t Wait. Through its three businesses—Pharmaceutical Services & Active Ingredients , Global Generics and Proprietary Products – the company offers a portfolio of products and services that include active pharmaceutical ingredients, (APIs), custom pharmaceutical services, generics, biosimilars and differentiated formulations. With operations in 26 countries across the globe, the major therapeutic areas of Dr. Reddy’s are gastro-intestinal, cardiovascular, diabetology, oncology, pain management and anti-infectives. For more information, log on to: www.drreddys.com

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words “may”, “will”, “should”, “expects”, “plans”, “intends”, “anticipates”, “believes”, “estimates”, “predicts”, “potential”, or “continue” and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates , interest rates , persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganisation , including related integration issues.

The company assumes no obligation to update any information contained herein.


About Hatchtech

Hatchtech Pty Ltd is an Australian specialty pharmaceutical product company developing technology for the control of invertebrate pests. The Company’s lead product is Xeglyze™ Lotion, a novel, next generation head lice product in development that aims to overcome the frustrating, costly and inconvenient cycles of retreatment for head lice infestation currently experienced by children and their parents. The Company’s investors include OneVentures Innovation Fund, University of Melbourne Endowment Trust, Queensland Biotechnology Fund, GBS Venture Partners, Uniseed, and Australian Super.

About Xeglyze Lotion

Despite its prevalence and high cost to the community, there have been few major advances in controlling head lice infestation in recent years. Most pediculicide products have little ovicidal activity and require two treatments (approximately 7 to 10 days apart), with the second application required to treat those lice that have hatched from eggs that survived the first treatment and were not physically removed by nit combing. Non-compliance with this regimen and the difficulty in choosing the optimal time for the second application, are major drawbacks in using these products. Hatchtech’s Xeglyze™ Lotion, a topical formulation containing abametapir; an inhibitor of metalloproteases, has demonstrated both ovicidal and lousicidal activity and offers the potential for a more effective treatment using only a single application.

Exhibit 99.4

 

LOGO

 

 

DR. REDDY’S LABORATORIES LTD.

8-2-337, Road No. 3, Banjara Hills,

Hyderabad - 500034. Telangana, India.

   CONTACT
   INVESTOR RELATIONS   MEDIA RELATIONS
   KEDAR UPADHYE
[email protected]

(Ph: +91-40-66834297)

  CALVIN PRINTER
[email protected]
(Ph: +91-40- 49002121)

Dr. Reddy’s announces the Launch of Esomeprazole

Magnesium Delayed-Release Capsules USP, 20 mg and 40 mg

Hyderabad, India, September 28, 2015

 

 

Dr. Reddy’s Laboratories (NYSE: RDY) announced today that it has launched ESOMEPRAZOLE MAGNESIUM DELAYED-RELEASE CAPSULES USP, 20 mg and 40 mg, a therapeutic equivalent generic version of NEXIUM® (esomeprazole magnesium) Delayed-Release Capsules in the US market on September 25, 2015, following the approval by the United States Food & Drug Administration (USFDA).

The NEXIUM ®(esomeprazole magnesium) Delayed-Release Capsules brand and generic had U.S. sales of approximately $5.2 Billion MAT for the most recent twelve months ending in July 2015 according to IMS Health*.

Dr. Reddy’s ESOMEPRAZOLE MAGNESIUM DELAYED-RELEASE CAPSULES USP, 20 mg and 40 mg are available in bottle count size of 30.

NEXIUM ® is a registered trademark of ASTRAZENECA AB CORPORATION

 

* IMS National Sales Perspectives: Retail and Non-Retail MAT July 2015

About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses—Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastro-intestinal, cardiovascular, diabetology, oncology, pain management and anti-infectives. Dr. Reddy’s operates in markets across the globe. Our major markets include – USA, Russia & CIS, Venezuela and India. For more information, log on to: www.drreddys.com

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words “may”, “will”, “should”, “expects”, “plans”, “intends”, “anticipates”, “believes”, “estimates”, “predicts”, “potential”, or “continue” and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates , interest rates , persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganisation , including related integration issues.

The company assumes no obligation to update any information contained herein.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

SEC Filings